S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
AI powerhouse NVIDIA will hit $1000 soon
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Roku stock and the mother of all entry opportunities
Rivian shares gets discounted; shares can move lower 
My wife was skeptical... until I showed her my account balance. (Ad)
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
The Trade Desk: 3 reasons to buy before a new all-time high
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
AI powerhouse NVIDIA will hit $1000 soon
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Roku stock and the mother of all entry opportunities
Rivian shares gets discounted; shares can move lower 
My wife was skeptical... until I showed her my account balance. (Ad)
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
The Trade Desk: 3 reasons to buy before a new all-time high
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
AI powerhouse NVIDIA will hit $1000 soon
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Roku stock and the mother of all entry opportunities
Rivian shares gets discounted; shares can move lower 
My wife was skeptical... until I showed her my account balance. (Ad)
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
The Trade Desk: 3 reasons to buy before a new all-time high
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
AI powerhouse NVIDIA will hit $1000 soon
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Roku stock and the mother of all entry opportunities
Rivian shares gets discounted; shares can move lower 
My wife was skeptical... until I showed her my account balance. (Ad)
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
The Trade Desk: 3 reasons to buy before a new all-time high
NASDAQ:AMGN

Amgen (AMGN) Stock Price, News & Analysis

$285.18
+1.72 (+0.61%)
(As of 02/22/2024 ET)
Today's Range
$281.39
$285.72
50-Day Range
$275.18
$324.56
52-Week Range
$211.71
$329.72
Volume
2.99 million shs
Average Volume
3.03 million shs
Market Capitalization
$152.83 billion
P/E Ratio
22.83
Dividend Yield
3.16%
Price Target
$295.30

Amgen MarketRank™ Stock Analysis

Analyst Rating
Hold
2.47 Rating Score
Upside/​Downside
3.5% Upside
$295.30 Price Target
Short Interest
Healthy
1.74% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.42
Upright™ Environmental Score
News Sentiment
0.60mentions of Amgen in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$572,271 Sold Last Quarter
Proj. Earnings Growth
7.43%
From $19.51 to $20.96 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.87 out of 5 stars

Medical Sector

28th out of 934 stocks

Biological Products, Except Diagnostic Industry

8th out of 160 stocks


AMGN stock logo

About Amgen Stock (NASDAQ:AMGN)

Amgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.

Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.

Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.

Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.

In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.

Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.

AMGN Stock Price History

AMGN Stock News Headlines

Are these frigid Dow stocks in for a longer winter? (AMGN)
These three Dow laggards have suffered double-digit percentage declines this winter, contributing to the Dow’s underperformance versus other major averages.
IBM, Verizon, Merck stocks lead Dow to new highs (AMGN)
The Dow hits record highs with IBM, Verizon, Merck, and insurer Travelers leading the way; those strong stocks don't make much of a dent in S&P performance
A sudden and dramatic change is coming to US bank accounts.
The financial elite (and US government) has a major change planned. It could strange new changes applied to your bank, overnight.
5 top healthcare stocks for earnings growth in 2024 (AMGN)
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed.
BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?
AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE
AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE
A sudden and dramatic change is coming to US bank accounts.
The financial elite (and US government) has a major change planned. It could strange new changes applied to your bank, overnight.
Short Interest in Amgen Inc. (NASDAQ:AMGN) Increases By 5.2%
Amgen (NASDAQ:AMGN) Downgraded by StockNews.com to "Hold"
AMGN vs. LLY: Which Biotech Stock Is a Better Buy Right Now?
AMGN Jan 2026 450.000 call
AMGN Feb 2024 135.000 call
Financial Analysis: Inhibrx (NASDAQ:INBX) vs. Amgen (NASDAQ:AMGN)
13 Highest Yielding Dividend Stocks in the Dow
Amgen set to snap six-day losing streak
See More Headlines
Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 12/8 Dividend
11/16/2023
Dividend Payable
12/08/2023
Last Earnings
2/06/2024
Ex-Dividend for 3/7 Dividend
2/15/2024
Today
2/22/2024
Dividend Payable
3/07/2024
Next Earnings (Estimated)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AMGN
CUSIP
03116210
Employees
26,700
Year Founded
1980

Price Target and Rating

Average Stock Price Target
$295.30
High Stock Price Target
$350.00
Low Stock Price Target
$200.00
Potential Upside/Downside
+3.5%
Consensus Rating
Hold
Rating Score (0-4)
2.47
Research Coverage
19 Analysts

Profitability

Net Income
$6.72 billion
Pretax Margin
27.86%

Debt

Sales & Book Value

Annual Sales
$28.19 billion
Cash Flow
$26.50 per share
Book Value
$11.63 per share

Miscellaneous

Free Float
533,454,000
Market Cap
$152.83 billion
Optionable
Optionable
Beta
0.62

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Should I Buy Amgen Stock? AMGN Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Amgen was last updated on Wednesday, February 21, 2024 at 1:28 PM.

Pros

Here are some ways that investors could benefit from investing in Amgen Inc.:

  • Amgen's diverse product portfolio includes Enbrel for treating plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis, which are high-demand therapeutic areas.
  • Recent collaborations with various pharmaceutical companies like Novartis, UCB, and Eli Lilly indicate potential for innovative drug development and market expansion.
  • Amgen's product Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization, addresses critical cardiovascular health issues.
  • Strong focus on biotechnology and biological products, except diagnostic, positions Amgen in a sector with high growth potential and technological advancements.
  • Current stock price trends show consistent growth, reflecting positive investor sentiment and potential for capital appreciation.

Cons

Investors should be bearish about investing in Amgen Inc. for these reasons:

  • Market competition in the biotechnology industry is intense, leading to potential challenges in maintaining market share and pricing power.
  • Regulatory uncertainties and changes in healthcare policies can impact Amgen's product pricing and market access, affecting revenue streams.
  • Dependency on a few key products like Enbrel and Neulasta for a significant portion of revenue poses risks in case of patent expirations or market disruptions.
  • Fluctuations in research and development outcomes can lead to delays in product launches or failures, impacting investor confidence and financial performance.
  • Biotechnology sector volatility and sensitivity to macroeconomic factors can result in stock price fluctuations, affecting investor returns and portfolio stability.














AMGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Amgen stock right now?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View AMGN analyst ratings
or view top-rated stocks.

What is Amgen's stock price target for 2024?

19 brokerages have issued 12 month price objectives for Amgen's stock. Their AMGN share price targets range from $200.00 to $350.00. On average, they predict the company's share price to reach $295.30 in the next year. This suggests a possible upside of 3.5% from the stock's current price.
View analysts price targets for AMGN
or view top-rated stocks among Wall Street analysts.

How have AMGN shares performed in 2024?

Amgen's stock was trading at $288.02 at the start of the year. Since then, AMGN shares have decreased by 1.0% and is now trading at $285.18.
View the best growth stocks for 2024 here
.

Are investors shorting Amgen?

Amgen saw a increase in short interest in January. As of January 31st, there was short interest totaling 9,300,000 shares, an increase of 5.2% from the January 15th total of 8,840,000 shares. Based on an average daily trading volume, of 2,620,000 shares, the days-to-cover ratio is currently 3.5 days. Approximately 1.7% of the shares of the company are sold short.
View Amgen's Short Interest
.

When is Amgen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our AMGN earnings forecast
.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings results on Tuesday, February, 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.66 by $0.05. The medical research company had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. Amgen had a trailing twelve-month return on equity of 154.27% and a net margin of 23.83%. The company's quarterly revenue was up 19.8% on a year-over-year basis. During the same period in the prior year, the firm posted $4.09 EPS.
Read the conference call transcript
.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Tuesday, December 12th. Shareholders of record on Friday, February 16th will be given a dividend of $2.25 per share on Thursday, March 7th. This represents a $9.00 annualized dividend and a dividend yield of 3.16%. The ex-dividend date of this dividend is Thursday, February 15th. This is an increase from the stock's previous quarterly dividend of $2.13.
Read our dividend analysis for AMGN
.

Is Amgen a good dividend stock?

Amgen (NASDAQ:AMGN) pays an annual dividend of $9.00 per share and currently has a dividend yield of 3.17%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 72.06%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 42.94% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY 2024 earnings guidance on Tuesday, February, 6th. The company provided earnings per share guidance of 18.900-20.300 for the period, compared to the consensus earnings per share estimate of 20.000. The company issued revenue guidance of $32.4 billion-$33.8 billion, compared to the consensus revenue estimate of $32.7 billion.

What is Robert A. Bradway's approval rating as Amgen's CEO?

1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

Who are Amgen's major shareholders?

Amgen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.16%), Primecap Management Co. CA (2.73%), Charles Schwab Investment Management Inc. (1.94%), Capital Research Global Investors (1.25%), Price T Rowe Associates Inc. MD (1.23%) and Northern Trust Corp (1.20%). Insiders that own company stock include Amgen Inc, Jonathan P Graham, Murdo Gordon, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams, Robert Eckert, Ronald D Sugar and Ronald D Sugar.
View institutional ownership trends
.

How do I buy shares of Amgen?

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Amgen have any subsidiaries?
The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen Canada Inc., Amgen Europe GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Research Munich GmbH, Amgen Rockville Inc., Amgen S.A., Amgen S.A.S., Amgen S.p.A., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology Ireland Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Five Prime Therapeutics Inc., Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, KAI Pharmaceuticals Inc., Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Saga Investments Coöperatief U.A., Synergen, TeneoBio, TeneoBio Inc., Tularik, deCODE Genetics ehf, and llypsa Inc..
Read More
This page (NASDAQ:AMGN) was last updated on 2/23/2024 by MarketBeat.com Staff